Clorox (NYSE:CLX) Given New $110.00 Price Target at The Goldman Sachs Group

Key Points

• The Goldman Sachs Group has lowered its price target for Clorox from $115.00 to $110.00, maintaining a "sell" rating, indicating a potential downside of 9.80%.
• Clorox shares recently traded down 1.1%, reaching $121.95 with a market capitalization of $14.92 billion.
• In the latest earnings report, Clorox surpassed earnings expectations, posting an EPS of $2.87, which was significantly higher than the consensus estimate of $2.24.

Clorox (NYSE:CLX - Get Free Report) had its price objective decreased by equities research analysts at The Goldman Sachs Group from $115.00 to $110.00 in a report released on Wednesday,MarketScreener reports. The firm currently has a "sell" rating on the stock. The Goldman Sachs Group's target price suggests a potential downside of 9.80% from the stock's previous close.

CLX has been the topic of several other research reports. UBS Group lowered their price objective on Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a research report on Thursday, July 17th. JPMorgan Chase & Co. lifted their price target on Clorox from $133.00 to $135.00 and gave the company a "neutral" rating in a research note on Monday, September 8th. Zacks Research raised Clorox from a "strong sell" rating to a "hold" rating in a research note on Monday. TD Cowen lowered their price objective on Clorox from $120.00 to $117.00 and set a "hold" rating for the company in a research report on Wednesday. Finally, Citigroup reiterated a "neutral" rating and issued a $135.00 target price (down from $140.00) on shares of Clorox in a report on Tuesday, July 15th. One investment analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Clorox presently has an average rating of "Reduce" and an average target price of $134.08.

Clorox Stock Down 1.1%

Shares of CLX traded down $1.36 on Wednesday, hitting $121.95. The company's stock had a trading volume of 63,258 shares, compared to its average volume of 1,682,647. The firm has a market capitalization of $14.92 billion, a price-to-earnings ratio of 18.76, a P/E/G ratio of 0.99 and a beta of 0.52. The firm's fifty day moving average price is $123.33 and its 200-day moving average price is $130.02. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. Clorox has a fifty-two week low of $116.53 and a fifty-two week high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.24 by $0.63. The firm had revenue of $1.99 billion for the quarter, compared to analysts' expectations of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.82 EPS. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, equities research analysts expect that Clorox will post 7.15 EPS for the current year.

Insiders Place Their Bets

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the completion of the sale, the chief operating officer owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.57% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLX. Wellington Management Group LLP boosted its stake in shares of Clorox by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 4,074 shares of the company's stock worth $662,000 after buying an additional 646 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its stake in Clorox by 36.4% during the first quarter. Fifth Third Wealth Advisors LLC now owns 1,712 shares of the company's stock worth $252,000 after acquiring an additional 457 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Clorox by 5.7% during the first quarter. Rhumbline Advisers now owns 273,462 shares of the company's stock valued at $40,267,000 after buying an additional 14,647 shares during the last quarter. Czech National Bank boosted its holdings in shares of Clorox by 5.4% in the first quarter. Czech National Bank now owns 28,294 shares of the company's stock valued at $4,166,000 after purchasing an additional 1,455 shares during the period. Finally, NBC Securities Inc. boosted its holdings in shares of Clorox by 123,850.0% in the first quarter. NBC Securities Inc. now owns 2,479 shares of the company's stock valued at $365,000 after purchasing an additional 2,477 shares during the period. Institutional investors own 78.53% of the company's stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.